Final Stage 2 Results of the CLL11 Trial

Article

Jennifer Brown, MD, PhD, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.

Clinical Pearls

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.

  • The CLL11 study provided the basis for the approval of GA101 (obinutuzumab)
  • GA101 has a different mechanism than rituximab or ofatumumab in that it confers increased direct cell death
  • GA101 + chlorambucil compared with chlorambucil alone now has demonstrated a statistically significant improvement in overall survival
  • In the direct comparison, GA101 + chlorambucil demonstrated an improvement in progression-free survival compared with rituximab + chlorambucil (27 months vs 16 months)
  • GA101 + chlorambucil also has demonstrated a higher complete remission rate and MRD negativity rate

<<<

Back to the conference page

Related Videos
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Related Content